Stockscreener 앱 받기
4.97
2.28%
-0.1162
시간 외 거래:
4.99
0.02
+0.40%
전일 마감가:
$5.0862
열려 있는:
$5.09
하루 거래량:
23,010
Relative Volume:
0.64
시가총액:
$507.53M
수익:
$180.81M
순이익/손실:
$-160.71M
주가수익비율:
-2.6536
EPS:
-1.8729
순현금흐름:
$-88.46M
1주 성능:
+3.97%
1개월 성능:
-4.97%
6개월 성능:
-46.04%
1년 성능:
-32.38%
1일 변동 폭
$4.9201
$5.09
1주일 범위
$4.90
$5.15
52주 변동 폭
$4.75
$12.25
발네바 Stock (VALN) Company Profile
Compare VALN vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
4.97 | 506.51M | 180.81M | -160.71M | -88.46M | -1.8729 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
발네바 Stock (VALN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-08-19 | 재개 | H.C. Wainwright | Buy |
| 2022-08-03 | 개시 | H.C. Wainwright | Buy |
발네바 주식(VALN)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, L - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - The National Law Review
Valneva's Trading Restriction Lifts at an Awkward Moment as Analysts Square Off Over Vaccine Prospec - ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - The National Law Review
AYJ0 Forecast — Price Target — Prediction for 2027 - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect - The National Law Review
A3CPD1 Forecast — Price Target — Prediction for 2027 - TradingView
Valneva SE Sponsored ADR Actuals & Estimates (NASDAQ:VALN) - TradingView
VALN Q1 2026 Earnings: Significant EPS Miss Highlights Development‑Stage Cash BurnEstimate Dispersion - newsline.com
VLA.PA Technical Analysis | Trend, Signals & Chart Patterns | VALNEVA SE (EPA:VLA) - ChartMill
VALNEVA:Declaration of shares and voting rights - GlobeNewswire Inc.
VALN Q1 2026 Earnings: Significant EPS Miss Drives Stock DeclinePreliminary Results - dars.gov.et
VALNValneva SE ADR Stock Price and Quote - Finviz
Valneva (VALN) Holds Steady Near Support as Traders Weigh Near-Term CatalystsMarket Cap Weight - The Legal Advocate
VLA.PA Stock Price, Quote & Chart | VALNEVA SE (EPA:VLA) - ChartMill
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Valneva SE earnings missed by $0.24, revenue fell short of estimates - Investing.com
Valneva Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips - Investing.com Nigeria
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - PR Newswire
Valneva’s €84M Cash Injection Comes With a Bitter Pill for Shareholders - AD HOC NEWS
Valneva faces securities fraud probe after Lyme vaccine trial misses key goal, shares drop 37%. - Pluang
Law firm probes Valneva over vaccine trial resu... - Pluang
Valneva shares slide after US pullback on chikungunya vaccine filing - MSN
Valneva (NASDAQ:VALN) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty - Investing.com
Valneva (NASDAQ:VALN) Shares Gap UpTime to Buy? - MarketBeat
Valneva's Dual Challenge: Legal Scrutiny Meets Commercial Reality - AD HOC NEWS
Guggenheim cuts Valneva stock price target to $11 on Lyme vaccine - Investing.com
Valneva faces investigation after Lyme vaccine trial misses primary goal, shares drop 37%. - Pluang
Valneva SE Under Investigation for Securities Fraud - Intellectia AI
VALN stock nosedives on mixed results from Lyme disease vaccine study - MSN
Law firm investigates Valneva over vaccine tria... - Pluang
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Valneva (NASDAQ:VALN) Shares Gap DownHere's Why - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Law firm probes Valneva investors' claims after Lyme vaccine trial misses primary goal, shares drop 37%. - Pluang
Valneva Faces Mounting Legal Pressure Following Clinical Trial Setback - AD HOC NEWS
2026-04-06 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation | NDAQ:VALN | Press Release - Stockhouse
Valneva's Travel Vaccines: Strategic Pivot to Emerging Markets Drives Long-Term Investor Value in Bi - AD HOC NEWS
발네바 (VALN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):